Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ocrevus Launching Quickly Even After Manufacturing Worries Delayed US Approval

Executive Summary

Genentech’s ocrelizumab, a CD20-directed antibody, becomes first US-approved treatment for primary progressive multiple sclerosis and is also indicated for relapsing disease. Labeling includes warnings about infusion reactions, infections and malignancy but lacks a boxed warning or REMS.

Advertisement

Related Content

Not Just Herceptin Biosimilar: Additional 12 Drugs Set For EU Marketing Approval After CHMP Nod
New Treatments For Psoriasis, Ovarian Cancer And MS Seeking CHMP Thumbs Up This Week
Where’s The Suffix? Valeant’s Siliq Approved Without Four-Letter Identifier
FDA’s Burden Estimate On Biologic Naming Ignores Downstream Costs, Critics Say
MS Drug Prices Far Exceed Value Thresholds, Even At Current Discounts – ICER Report
Biologic Product Naming: US FDA Sticks With Suffixes ‘Devoid Of Meaning’
Roche’s Highly Anticipated Ocrelizumab Delayed By Manufacturing Issues
Roche’s Ocrelizumab Poised To Seize Primary Progressive MS Opportunity
Ocrelizumab May Represent Roche’s Rebound In Neuroscience
Despite Ocrelizumab Infection Risk, Roche Sees Multiple Sclerosis Opportunity

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS120338

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel